Tagged with IP

Pharma The AIFP’s Jakub Dvořáček explains the recently launched tool for information disclosure between pharmaceutical companies and doctors, highlighting the significance it holds for industry and country. Furthermore, he reviews the Czech Republic’s attractiveness as a location for pharma companies. When we met you in 2012, you named re-exporting and a…

Pharma Simona Falciai, General Manager of Shionogi, provides insights into the launch of the Italian affiliate, how the company is catering to a key unmet medical need with Ospemifene, the first oral, non-estrogenic drug in the field of vulvar and vaginal atrophy, and the central role of partnerships in the company’s…

Pharma Giorgio Bruno, CEO of Recipharm Italy, gives an insight into the success factors of the CDMO, discusses the recent acquisition of Mitim, and explains how this acquisition helps Recipharm not only achieve their growth ambitions but also provide better services to its clients. You were appointed CEO of Recipharm Italy…

Pharma Thierry Guillot, president of Chugai Pharma France, talks about the challenge of transitioning from a small organization, which revolved around one main product into a larger entity capable of delivering multiple products and solutions; he also reveals how since 2008, Chugai and Roche have worked together on marketing and business…

Pharma In keeping with its reputation as a forerunner, the Dutch healthcare eco-system is currently reinventing itself to ensure it remains ahead of the game in terms of both innovation and excellence. Market and patient access, transparency, cost-effectiveness and process innovation all feature prominently as industry and government alike band together…

France Marc de Garidel reveals how 2015 has been Ipsen’s best year since becoming publicly traded, marked by their take-off in the US, and how in 2016 the US will overtake France to become their number one affiliate. Mr de Garidel also explains Ipsen’s key growth drivers for the next five…

Pharma The founder of the Middle East’s largest pharmaceutical company, EIPICO, discusses the evolution of the Egyptian pharmaceutical industry over the last 50 years, and his hopes for the industry over the coming decades. Dr. Borhan, you became Chairman of El Kahira Pharmaceuticals in 1962, and established EIPICO in 1980. In…

Pharma The President and MD of Abiogen Pharma discusses his family company’s recent milestones, the reasons for persisting with local manufacturing, and the benefits of international partnerships. You created Abiogen back in 1997, following the acquisition of Istituto Gentili by MSD, in order to maintain your family’s entrepreneurial tradition and build…

Pharma Stéphane Thiroloix, CEO of the independent and family owned Mayoly Spindler, reveals how their vision is to become a reference company internationally in the field of gastroenterology and dermocosmetics; how already forty-five percent of their business is done overseas; and how on current projections, excluding external growth, they anticipate to…

Pharma In an exclusive interview, the Vice President of Philips Research explains the key to continuous evolution, improving healthcare stakeholder relations, and fostering “Open Innovation.” You have been Vice President of Philips Research since 2007, a centenarian institution that stands as one of the largest private research organizations in the world.…

Pharma Takeda’s goal is to become a trusted and reliable partner in the healthcare system by better understanding patients’ needs. Aarnoud Overkamp, general manager of the Dutch subsidiary, shares his perspective on the challenges faced by the local healthcare system, the importance of Takeda-ism in the organization, and finding innovative ways…

Pharma The chairman of Egypt’s largest holding company for pharmaceutical manufacturers, ACDIMA, shares his vision for how Egyptian manufacturers can enhance their competitiveness in the coming years, and extend their activities further up the value chain into API production and R&D activities. How well prepared are Egyptian companies to compete in…